Website : www.jocm.vn Email : jocm@bachmai.edu.vn Phone : +84947040855
https://doi.org/10.52322/jocmbmh.07.en.07
Introduction: One of the most commonly recommended DAAs in the treatment guidelines for chronic hepatitis C is daclatasvir (DAC) in combination with sofosbuvir (SOF).
Objectives: To evaluate the treatment effects of Sofosbuvir/Dalatasvir regimen in patients with chronic HCV infection with HIV co-infection at Dong Da General Hospital, Hanoi.
Material and Methods: Descriptive and prospective studies on 60 HCV/HIV co-infected subjects receiving Sofosbuvir/Daclatasvir regimen from June 2018 to May 2020.
Result: 100% of patients with clinical stage 1, clinical symptoms and opportunistic infections changed significantly after 4 weeks of treatment, 100% of follow-up patients had no clinical manifestations and opportunistic infections at T4 and stabilization later. Mean CD4 cell count at the end of follow-up increased significantly with the start of treatment (p<0.01). HIV- RNA load at the end of follow-up of cirrhosis and hepatitis 100% group reached levels below detection threshold. The sustained viral response after 12 weeks of treatment (SVR 12) of both groups was 100%. The mean value of liver enzymes after treatment decreased compared to the time of T0 (p<0.01); and 100% of patients had normal liver enzymes at time of SVR12. APRI index decreased significantly compared to the time of T0 (p<0.01); based on Fibroscan results, the rate of hepatitis and cirrhosis is unchanged.
Conclusion: SVR12 outcomes of HCV/HIV co-infected patients showed a good response with Sofosbuvir/Daclatasvir regimen.